Premium
Annovis Bio Inc (ANVS)
NYSE
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also deve... Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company’s lead product candidate is Buntanetap, which is in phase 3 to treat alzheimer’s disease, as well as in open-label phase 3 to treat parkinson’s disease. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer’s disease and dementia. Annovis Bio, Inc. was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.19 | 10.9195402299 | 1.74 | 1.96 | 1.645 | 966184 | 1.77748678 | CS |
| 4 | 0.03 | 1.57894736842 | 1.9 | 2.065 | 1.645 | 996214 | 1.80077758 | CS |
| 12 | 0 | 0 | 1.93 | 2.4705 | 1.5407 | 1258451 | 1.8947284 | CS |
| 26 | -1.52 | -44.0579710145 | 3.45 | 4.14 | 1.5407 | 836046 | 2.14400338 | CS |
| 52 | -0.41 | -17.5213675214 | 2.34 | 5.5 | 1.5407 | 956281 | 2.64563897 | CS |
| 156 | -12.22 | -86.3604240283 | 14.15 | 22.49 | 1.11 | 655964 | 5.59359003 | CS |
| 260 | -89.18 | -97.8816814839 | 91.11 | 132 | 1.11 | 454661 | 10.32750707 | CS |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
